IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Adell Harriman & Carpenter Inc.

Adell Harriman & Carpenter Inc. decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 35.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,615 shares of the medical research company’s stock after selling 905 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in IQVIA were worth $374,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at $13,759,000. Schwartz Investment Counsel Inc. raised its stake in shares of IQVIA by 4.1% during the 4th quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock valued at $41,345,000 after buying an additional 7,050 shares during the last quarter. Gilliland Jeter Wealth Management LLC acquired a new stake in IQVIA during the fourth quarter worth about $986,000. Dfpg Investments LLC acquired a new position in IQVIA in the fourth quarter valued at approximately $1,106,000. Finally, Sei Investments Co. increased its holdings in shares of IQVIA by 20.2% during the 3rd quarter. Sei Investments Co. now owns 94,748 shares of the medical research company’s stock valued at $18,641,000 after purchasing an additional 15,913 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders sold a total of 41,285 shares of company stock valued at $10,331,003 over the last 90 days. 1.60% of the stock is owned by company insiders.

IQVIA Trading Down 0.4 %

IQV traded down $0.84 during trading hours on Tuesday, reaching $234.64. The company’s stock had a trading volume of 55,735 shares, compared to its average volume of 956,152. The stock has a market cap of $42.59 billion, a PE ratio of 32.30, a P/E/G ratio of 2.27 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The business’s 50-day moving average is $245.21 and its 200-day moving average is $223.56.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.54 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the company. UBS Group raised their price objective on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Barclays boosted their target price on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Robert W. Baird raised their price target on shares of IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Truist Financial boosted their price objective on IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Finally, Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $256.80.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.